Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 5/2010

01-05-2010 | Review Article

Management of Headache in the Elderly

Authors: Dr Matthew S. Robbins, Richard B. Lipton

Published in: Drugs & Aging | Issue 5/2010

Login to get access

Abstract

The diagnosis and management of headache disorders in the elderly are challenging. The evaluation of the elderly patient with new-onset or recurrent headache requires a grasp of the heterogeneous set of causes of secondary head pain disorders. Once such aetiologies are excluded, the correct primary headache disorder must be diagnosed. Although tension-type headache is the leading cause of new-onset headache in the elderly, other primary headache disorders such as migraine can manifest in later life, and one disorder, hypnic headache, occurs almost exclusively in the elderly. Primary chronic daily headache persists in elderly patients to a greater extent than the primary episodic headache disorders do. The treatment of elderly patients with primary headache disorders is multifaceted, including acute, prophylactic and at times transitional treatments. Knowledge of drug interactions is particularly important as polypharmacy is the rule. Concomitant illnesses may require adjustments in choice or dose of drugs. In addition, as many acute and preventive treatments are either contra-indicated or poorly tolerated in the elderly, modifiable risk factors for headache progression and perpetuation must be addressed. In spite of these treatment complexities, there are numerous opportunities to bring relief to older patients with primary headache disorders from the currently available therapies. New treatment options for elderly patients with headache will soon be available, including acute, prophylactic and interventional techniques.
Literature
1.
Pascual J, Combarros O, Leno C, et al. Distribution of headache by diagnosis as the reason for neurologic consultation. Med Clin (Barc) 1995 Feb; 104(5): 161–4
2.
Prencipe M, Casini A, Ferretti C, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001 Mar; 70(3): 377–81PubMedCrossRef
3.
Solomon G, Kunkel RJ, Frame J. Demographics of headache in elderly patients. Headache 1990 Apr; 30(5): 273–6PubMedCrossRef
4.
The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24Suppl. 1: 9–160
5.
Swanson JW, Caopbianco DJ, Evers S. Headaches in the elderly. In: Silberstein SD, Lipton RB, Dodick DW, editors. Wolffs headache and other head pain. 8th ed. New York: Oxford University Press, Inc., 2008: 711–20
6.
Durcan F, Corbett J, Wall M. The incidence of pseudotumor cerebri: population studies in Iowa and Louisiana. Arch Neurol 1988 Aug; 45(8): 875–7PubMedCrossRef
7.
Galvin JA, Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 2004 Aug 30; 223(2): 157–60PubMedCrossRef
8.
Schievink W. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA 2006 May; 295(19): 2286–96PubMedCrossRef
9.
Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002 Jul; 347(4): 261–71PubMedCrossRef
10.
Solomon S, Cappa K. The headache of temporal arteritis. J Am Geriatr Soc 1987 Feb; 35(2): 163–5PubMed
11.
Salvarani C, Hunder G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001 Apr; 45(2): 140–5PubMedCrossRef
12.
Schwartz B, Stewart W, Simon D, et al. Epidemiology of tension-type headache. JAMA 1998 Feb; 279(5): 381–3PubMedCrossRef
13.
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007 Jan 30; 68(5): 343–9PubMedCrossRef
14.
Schwaiger J, Kiechl S, Seppi K, et al. Prevalence of primary headaches and cranial neuralgias in men and women aged 55–94 years (Bruneck study). Cephalalgia 2009 Feb; 29(2): 179–87PubMedCrossRef
15.
Lyngberg A, Rasmussen B, Jørgensen T, et al. Incidence of primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol 2005 Jun; 161(11): 1066–73PubMedCrossRef
16.
Bigal M, Rapoport A, Hargreaves R. Advances in the pharmacologic treatment of tension-type headache. Curr Pain Headache Rep 2008 Dec; 12(6): 442–6PubMedCrossRef
17.
Cerbo R, Barbanti P, Fabbrini G, et al. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenetic implications. Headache 1998 Jun; 38(6): 453–7PubMedCrossRef
18.
19.
Stewart WF, Wood C, Reed ML, et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008 Nov; 28(11): 1170–8PubMedCrossRef
20.
Fisher CM. Late-life migraine accompaniments: further experience. Stroke 1986 Sep–Oct; 17(5): 1033–42PubMedCrossRef
21.
Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology 2006 Jul 25; 67(2): 246–51PubMedCrossRef
22.
Martins KM, Bordini CA, Bigal ME, et al. Migraine in the elderly: a comparison with migraine in young adults. Headache 2006 Feb; 46(2): 312–6PubMedCrossRef
23.
Fischera M, Marziniak M, Gralow I, et al. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 2008 Jun; 28(6): 614–8PubMedCrossRef
24.
Swanson JW, Yanagihara T, Stang PE, et al. Incidence of cluster headaches: a population-based study in Olmsted County, Minnesota. Neurology 1994 Mar; 44 (3 Pt 1): 433–7PubMedCrossRef
25.
Matharu MS, Goadsby PJ. Trigeminal autonomic cephalalgias: diagnosis and management. In: Silberstein SD, Lipton RB, Dodick DW, editors. Wolff’s headache and other head pain. 8th ed. New York: Oxford University Press, Inc. USA, 2008: 379–430
26.
Evers S, Frese A, Majewski A, et al. Age of onset in cluster headache: the clinical spectrum (three case reports). Cephalalgia 2002 Mar; 22(2): 160–2PubMedCrossRef
27.
Fischera M, Anneken K, Evers S. Old age of onset in cluster-headache patients. Headache 2005 May; 45(5): 615PubMedCrossRef
28.
Seidler S, Marthol H, Pawlowski M, et al. Cluster headache in a ninety-one-year-old woman. Headache 2006 Jan; 46(1): 179–80PubMedCrossRef
29.
Favier I, van Vliet JA, Roon KI, et al. Trigeminal autonomic cephalgias due to structural lesions: a review of 31 cases. Arch Neurol 2007 Jan; 64(1): 25–31PubMedCrossRef
30.
Dodick D, Capobianco D. Treatment and management of cluster headache. Curr Pain Headache Rep 2001 Feb; 5(1): 83–91PubMedCrossRef
31.
32.
33.
Newman L, Lipton R, Solomon S. The hypnic headache syndrome: a benign headache disorder of the elderly. Neurology 1990 Dec; 40(12): 1904–5PubMedCrossRef
34.
Dodick D, Mosek A, Campbell J. The hypnic (“lalarm clock”) headache syndrome. Cephalalgia 1998 Apr; 18(3): 152–6PubMedCrossRef
35.
Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003 Mar 25; 60(6): 905–9PubMedCrossRef
36.
Silberstein S, Lipton R, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996 Oct; 47(4): 871–5PubMedCrossRef
37.
Wang S, Fuh J, Lu S, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000 Jan; 54(2): 314–9PubMedCrossRef
38.
Scher AI, Stewart WF, Liberman J, et al. Prevalence of frequent headache in a population sample. Headache 1998; 38(7): 497–506PubMedCrossRef
39.
Lu S, Fuh J, Chen W, et al. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 2001 Dec; 21(10): 980–6PubMedCrossRef
40.
Castillo J, Muñoz P, Guitera V, et al. Kaplan Award 1998: epidemiology of chronic daily headache in the general population. Headache 1999 Mar; 39(3): 190–6PubMedCrossRef
41.
Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009 Oct; 29(10): 1021–7PubMedCrossRef
42.
Aurora S, Schim J, Cutrer F, et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 1 trial double-blind phase [abstract]. Cephalalgia 2009; 29Suppl. 1: 29
43.
Dodick D, Smith T, Becker W, et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase [abstract]. Cephalalgia 2009; 29Suppl. 1: 29
44.
Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol 2009 Jan; 11(1): 18–23PubMedCrossRef
45.
Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008 Feb; 9(1): 37–41PubMedCrossRef
46.
Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005; 28(6): 277–9PubMedCrossRef
47.
Saper J, Silberstein S, Lake Ar, et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994 Oct; 34(9): 497–502PubMedCrossRef
48.
Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology 2008 Sep 9; 71(11): 848–55PubMedCrossRef
49.
Sjaastad O, Spierings EL. “Hemicrania continua”: another headache absolutely responsive to indomethacin. Cephalalgia 1984 Mar; 4(1): 65–70PubMedCrossRef
50.
Peres MF, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. Neurology 2001 Sep 25; 57(6): 948–51PubMedCrossRef
51.
Prakash S, Shah ND, Soni RK. Secondary hemicrania continua: case reports and a literature review. J Neurol Sci 2009 May 15; 280(1–2): 29–34PubMedCrossRef
52.
Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs 2003; 63(16): 1637–77PubMedCrossRef
53.
Grande RB, Aaseth K, Lundqvist C, et al. Prevalence of new daily persistent headache in the general population: the Akershus study of chronic headache. Cephalalgia 2009 Nov; 29(11): 1149–55PubMedCrossRef
54.
Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002 Feb; 22(1): 66–9PubMedCrossRef
55.
Meineri P, Torre E, Rota E, et al. New daily persistent headache: clinical and serological characteristics in a retrospective study. NeurolSci 2004 Oct; 25Suppl. 3: S281–2
56.
Bigal ME, Lipton RB, Tepper SJ, et al. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 2004 Sep 14; 63(5): 843–7PubMedCrossRef
57.
Tepper D, Tepper S, Sheftell F, et al. Headache attributed to hypothyroidism. Curr Pain Headache Rep 2007 Aug; 11(4): 304–9PubMedCrossRef
58.
Robbins MS, Lipton RB, Napchan U, et al. Prognosis in new daily-persistent headache: persistent, remitting, and relapsing-remitting subforms. Cephalalgia 2009 Oct; 29Suppl. 1: 106–7
59.
Rapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci 2006 May; 27Suppl. 2: S123–9PubMedCrossRef
60.
Lipton R, Stewart W, Cady R, et al. Wolfe Award: sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000; 40(10): 783–91PubMedCrossRef
61.
Brennum J, Brinck T, Schriver L. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996; 3: 23–6CrossRef
62.
Maas HJ, Danhof M, Della Pasqua OE. Analysis of the relationship between age and treatment response in migraine. Cephalalgia 2009 Jul; 29(7): 772–80PubMedCrossRef
63.
Haan J, Hollander J, Ferrari MD. Migraine in the elderly: a review. Cephalalgia 2007 Feb; 27(2): 97–106PubMedCrossRef
64.
Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 1998 Mar; 63(3): 342–53PubMedCrossRef
65.
Hall G, Brown M, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004 Feb; 62(4): 563–8PubMedCrossRef
66.
Musson D, Birk K, Panebianco D, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther 2001 Oct; 39(10): 447–52PubMed
67.
Dodick D, Lipton R, Martin V, et al. Consensus statement: cardiovascular safety profile oftriptans (5-HT agonists) in the acute treatment of migraine. Headache 2004 May; 44(5): 414–25PubMedCrossRef
68.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285(19): 2486–97CrossRef
69.
Papademetriou V. Cardiovascular risk assessment and triptans. Headache 2004 May; 44Suppl. 1: S31–9PubMedCrossRef
70.
Orlando LA, Matchar DB. When to stress over triptans: a Markov analysis of cardiovascular risk in migraine treatment. Headache 2004 Jul–Aug; 44(7): 652–60PubMedCrossRef
71.
Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003 Feb; 43(2): 144–66PubMedCrossRef
72.
Pradalier A, Clapin A, Dry J. Treatment review: non-steroid anti-inflammatory drugs in the treatment and longterm prevention of migraine attacks. Headache 1988 Sep; 28(8): 550–7PubMedCrossRef
73.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 Sep 26; 55(6): 754–62PubMedCrossRef
74.
Kellstein D, Lipton R, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 2000 May; 20(4): 233–43PubMedCrossRef
75.
Codispoti J, Prior M, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial. Headache 2001; 41(7): 665–79PubMedCrossRef
76.
Verhagen A, Damen L, Berger M, et al. Is any one analgesic superior for episodic tension-type headache? J Fam Pract 2006 Dec; 55(12): 1064–72PubMed
77.
Dodick D. Indomethacin-responsive headache syndromes. Curr Pain Headache Rep 2004 Feb; 8(1): 19–26PubMedCrossRef
78.
Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005 Jul–Aug; 45(7): 850–61PubMedCrossRef
79.
Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007 May–Jun; 59(3): 247–58PubMed
80.
Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991 Feb 15; 114(4): 257–63PubMed
81.
Farkouh M, Greenberg B. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009 May; 103(9): 1227–37PubMedCrossRef
82.
Laska E, Sunshine A, Mueller F, et al. Caffeine as an analgesic adjuvant. JAMA 1984 Apr; 251(13): 1711–8PubMedCrossRef
83.
84.
Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004 Dec 14; 63(11): 2022–7PubMedCrossRef
85.
Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005 Mar; 81(3): 578–82PubMed
86.
Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 2009 Aug; 29(8): 891–7PubMedCrossRef
87.
Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008 Sep; 48(8): 1157–68PubMedCrossRef
88.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 Dec 8–22; 163(22): 2716–24PubMedCrossRef
89.
90.
Sarchielli P, Mancini M, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 2006; 23(6): 461–89PubMedCrossRef
91.
92.
Aguilar E, Keshavan M, Martínez-Quiles M, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994 Dec; 151(12): 1819–21PubMed
93.
Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009 Jun; 85(1004): 322–6PubMedCrossRef
94.
Cohen A, Matharu M, Burns B, et al. Randomized doubleblind, placebo-controlled trial of high-flow inhaled oxygen in acute cluster headache [abstract]. Cephalalgia 2007; 27: 1188CrossRef
95.
Akerman S, Holland PR, Lasalandra MP, et al. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not during direct dural activation of trigeminal afferents. Headache 2009 Sep; 49(8): 1131–43PubMedCrossRef
96.
97.
Galletti F, Cupini LM, Corbelli I, et al. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009 Oct; 89(2): 176–92PubMedCrossRef
98.
Lucas C, Chaffaut C, Artaz MA, et al. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia 2005 Apr; 25(4): 267–79PubMedCrossRef
99.
Morillo LE, Alarcon F, Aranaga N, et al. Clinical characteristics and patterns of medication use of migraineurs in Latin America from 12 cities in 6 countries. Headache 2005 Feb; 45(2): 118–26PubMedCrossRef
100.
Bendtsen L, Jensen R. Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 2000 Jul; 20(6): 603–10PubMedCrossRef
101.
Bettucci D, Testa L, Calzoni S, et al. Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension-type headache: evaluation of efficacy and impact on quality of life. J Headache Pain 2006 Feb; 7(1): 34–6PubMedCrossRef
102.
Ad hoc committee of the Italian Society for the Study of Headaches (SISC). Diagnostic and therapeutic guidelines for migraine and cluster headache. J Headache Pain 2001; 2(3): 105–92CrossRef
103.
Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004 May; 62(10): 1706–11PubMedCrossRef
104.
Buchanan T, Ramadan N. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol 2006 Apr; 26(2): 188–98PubMedCrossRef
105.
Darowski A, Chambers S, Chambers D. Antidepressants and falls in the elderly. Drugs Aging 2009; 26(5): 381–94PubMedCrossRef
106.
Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996 Dec; 31(6): 444–69PubMedCrossRef
107.
Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007 Apr; 28(4): 188–95PubMedCrossRef
108.
Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996 Oct; 36(9): 547–55PubMedCrossRef
109.
110.
111.
Di Trapani G, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 2000 May–Jun; 151(3): 145–8PubMed
112.
Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001 Feb; 41(2): 119–28PubMedCrossRef
113.
Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997 Apr; 17(2): 109–12PubMedCrossRef
114.
Wheeler S. Lamotrigine efficacy in migraine prevention [abstract]. Cephalalgia 2001; 21: 374
115.
Brighina F, Palermo A, Aloisio A, et al. Levetiracetam in the prophylaxis of migraine with aura: a 6-month openlabel study. Clin Neuropharmacol 2006 Nov–Dec; 29(6): 338–42PubMedCrossRef
116.
117.
118.
Evans RW, Rizzoli P, Loder E, et al. Beta-blockers for migraine. Headache 2008 Mar; 48(3): 455–60PubMedCrossRef
119.
Tfelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache: clinical pharmacology and possible mode of action. Headache 2009 Jan; 49(1): 117–25PubMedCrossRef
120.
Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology 2007 Aug 14; 69(7): 668–75PubMedCrossRef
121.
Leone M, Grazzi L, La Mantia L, et al. Flunarizine in migraine: a minireview. Headache 1991 Jun; 31(6): 388–91PubMedCrossRef
122.
Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia 2008 Nov; 28(11): 1126–35PubMedCrossRef
123.
Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001 Jan 6; 322(7277): 19–22PubMedCrossRef
124.
Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003 Jan 1; 289(1): 65–9PubMedCrossRef
125.
Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 2009 Sep; 29(9): 921–7PubMedCrossRef
126.
Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008; 8: 4PubMedCrossRef
127.
Tronvik E, Stovner LJ, Schrader H, et al. Involvement of the renin-angiotensin system in migraine. J Hypertens Suppl 2006 Mar; 24(1): S139–43PubMedCrossRef
128.
Farlow M, Graham S, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf 2008; 31(7): 577–85PubMedCrossRef
129.
Lindelof K, Bendtsen L. Memantine for prophylaxis of chronic tension-type headache: a double-blind, randomized, crossover clinical trial. Cephalalgia 2009 Mar; 29(3): 314–21PubMedCrossRef
130.
Charles A, Flippen C, Romero Reyes M, et al. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 2007 Sep; 8(4): 248–50PubMedCrossRef
131.
Bigal M, Rapoport A, Sheftell F, et al. Memantine in the preventive treatment of refractory migraine. Headache 2008 Oct; 48(9): 1337–42PubMedCrossRef
132.
Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009 May; 72(19): 1630–3PubMedCrossRef
133.
Sun-Edelstein C, Mauskop A. Foods and supplements in the management of migraine headaches. Clin J Pain 2009 Jun; 25(5): 446–52PubMedCrossRef
134.
Sandor P, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005 Feb; 64(4): 713–5PubMedCrossRef
135.
Leone M, D’Amico D, Moschiano F, et al. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996 Nov; 16(7): 494–6PubMedCrossRef
136.
137.
Obermann M, Diener HC. Is botulinum toxin useful in treating headache? No. Curr Treat Options Neurol 2009 Jan; 11(1): 24–31CrossRef
138.
Aurora S, Winner P, Freeman M, et al. Botulinum neurotoxin type A for treatment of chronic migraine: pooled analyses of the PREEMPT clinical program 32-week open-label phase. Cephalalgia 2009; 29Suppl. 1: 7–8
139.
Harden RN, Cottrill J, Gagnon CM, et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, doubleblind, placebo-controlled pilot study. Headache 2009 May; 49(5): 732–43PubMedCrossRef
140.
Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 May 6; 70(19): 1707–14PubMedCrossRef
141.
Hussain A, Young WB. Steroids and aseptic osteonecrosis (AON) in migraine patients. Headache 2007 Apr; 47(4): 600–4PubMed
142.
Tobin J, Flitman S. Occipital nerve blocks: when and what to inject? Headache 2009 Nov–Dec; 4910: 1521–33PubMedCrossRef
143.
Haut S, Bigal M, Lipton R. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006 Feb; 5(2): 148–57PubMedCrossRef
144.
Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003 Mar; 43(3): 179–90PubMedCrossRef
145.
Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 2001 Mar; 41(3): 303–9PubMedCrossRef
146.
Ashina S, Buse D, Maizels M, et al. Depression: a risk factor for migraine chronification. Results from the American Migraine Prevalence and Prevention (AMPP) Study [abstract]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON). In press
147.
Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008 Apr 22; 70(17): 1525–33PubMedCrossRef
148.
Bevilaqua-Grossi D, Lipton RB, Napchan U, et al. Temporomandibular disorders and cutaneous allodynia are associated in individuals with migraine. Cephalalgia. Epub 2009 Jul 9
149.
Behin F, Behin B, Bigal ME, et al. Surgical treatment of patients with refractory migraine headaches and intranasal contact points. Cephalalgia 2005 Jun; 25(6): 439–43PubMedCrossRef
150.
Edvinsson L, Petersen KA. CGRP-receptor antagonism in migraine treatment. CNS Neurol Disord Drug Targets 2007 Aug; 6(4): 240–6PubMedCrossRef
151.
Silberstein SD. Tonabersat, a novel gap-junction modulator for the prevention of migraine. Cephalalgia 2009 Nov; 29Suppl. 2: 28–35PubMedCrossRef
152.
Hauge A, Asghar M, Schytz H, et al. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 2009 Aug; 8(8): 718–23PubMedCrossRef
153.
NINDS CRC Chronic Migraine Treatment Trial (CMTT) [ClinicalTrials.gov identifier NCT00772031]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2009 Oct 27]
154.
Bartsch T, Paemeleire K, Goadsby PJ. Neurostimulation approaches to primary headache disorders. Curr Opin Neurol 2009 Jun; 22(3): 262–8PubMedCrossRef
155.
Teepker M, Hotzel J, Timmesfeld N, et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia. Epub 2009 Jun 8
Metadata
Title
Management of Headache in the Elderly
Authors
Dr Matthew S. Robbins
Richard B. Lipton
Publication date
01-05-2010
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 5/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11315980-000000000-00000

Other articles of this Issue 5/2010

Drugs & Aging 5/2010 Go to the issue

Therapy In Practice

Implications of Opioid Analgesia for Medically Complicated Patients

Original Research Article

Effect of Prophylactic Treatment with Low-Molecular-Weight Heparin Bemiparin Sodium on Serum Potassium Levels

Leading Article

Targeting Tau Protein in Alzheimer’s Disease

Original Research Article

Potentially Inappropriate Medications and Risk of Hospitalization in Retirees

Review Article

Overcoming Gaps in the Management of Chronic Obstructive Pulmonary Disease in Older Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits